Asker Healthcare Group (ASKER) Fair Value & Analysis

Healthcare · SE · Market cap 30.4B SEK

A solid business, but screening 70% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (kr 32.11). The favourable scenario is already priced in.
• Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (kr 16.49 to kr 32.11) leaves room in how you read the outcome.

Price vs Fair Value (16 months)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

16‑month range kr 59.16 – kr 130.59 · fair‑value band kr 16.49 – kr 32.11 · the kr 84.70 price screens above the kr 25.69 fair value. Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Asker Healthcare Group (ASKER) currently trades at kr 84.70, while our model-based Fair Value estimate is kr 25.69, implying the stock looks roughly 69.7% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Asker Healthcare Group generated revenue of 17.3B SEK at a net margin of 3.4%. Revenue grew 13.2% year over year. It earns a return on equity of 9.3%. Net debt stands at 4.9B SEK. Fundamentals as of Jul 12, 2026

Our scenario range runs from kr 16.49 (bear case) to kr 32.11 (bull case); at kr 84.70, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 35% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at -70%, ASKER screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (kr 35.36) versus Asset-Based (kr 11.47). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care.

Full company description

Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care. The company supplies and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products. In addition, it develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services. Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; and products for physiotherapy practices, as well as supplies exercise and treatment equipment and measurement. Additionally, it sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products. The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, France, Slovakia, Czech Republic, and Poland. Asker Healthcare Group AB (publ) was founded in 2006 and is headquartered in Danderyd, Sweden.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Asker Healthcare Group reported revenue of kr 16.8B in FY2025 versus kr 9.4B in FY2021, a compound +15.7%/yr. Reported net income was kr 492M in FY2025, compounding +1.3%/yr from FY2021.

ASKER screens 70% overvalued. Compare with McKesson Corporation →

Peer Group

Medical Distribution · 81 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Distribution median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.